Accelera, a leader in preclinical research and a NMS group member, today announced the appointment of Claudio Bernardi as industry representative of the National Expert Committee for the PARERE Network - the EURL ECVAM (the European Union Reference Laboratory: European Centre for the Validation of Alternative Methods) Network for alternative methods to animal testing.
Until today, global regulatory authorities still require all new candidate drugs to undergo extensive tests in animals before the approval to protect patients from adverse effects. At the same time, authorities and companies also make their own and joint efforts to find alternative methods. The Preliminary Assessment of Regulatory Relevance (PARERE) Network is a solid example of such collaboration among the regulatory, academic and industry sectors.
Proposed test methods and testing strategies are shared and discussed, and potential regulatory relevance and suitability are evaluated through this network in all regulatory sectors. The committee also assists the information flow between EURL-ECVAM and regulators regarding the development and validation of methods in identifying areas that need specific attention and in identifying regulatory experts to participate in specific EURL-ECVAM project groups. All these activities are essential to facilitate new and alternative methods that can eventually replace tests on animals.
“All experts appointed in this committee are key opinion leaders with broad experience in the sectors to shoulder this task, and our colleague Claudio Bernardi is no exception.” said Enrico Pesenti, CEO of Accelera. “His nomination as the sole representative from the industry confirms the authorities’ recognition of the ongoing endeavors of him, Accelera and NMS Group to find a better treatment for us all. We look forward to a valid solution in the near future.”
“Tremendous amount of work has been dedicated in the last decades at all levels to translate the Russell & Burch paradigm of the 3Rs (replace, reduce, and refine) into concrete actions and experimental procedures.” said Claudio Bernardi, Chair of the Animal Welfare Body of Accelera. “I am honored to be part of this Committee and will help to monitor and ensure priorities and requirement set by the authorities in the R&D process of innovative therapies are thoroughly considered during the selection of alternative methods, as what have always been doing here at Accelera and NMS Group.”